LAS VEGAS, NV, Oct. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – One World Pharma Inc. (OWPC), “OWP,” a fully licensed cannabis and hemp producer in Colombia is pleased to announce that it has entered into an exclusive, multi-year agreement with the WALA POPAYAN Co-operative (“co-op”), a highly skilled agrarian community in the Colombian Andes to collaborate in the cultivation and refinement of hemp-derived ingredients.
The agreement creates a partnership in which OWP blends the ancestral techniques of the Nasa people with modern technology, registered plant genetics and international standard operating procedures. The collaboration creates a true partnership that is expected to maximize the opportunity to grow in one of the most ideal climates for agriculture in the world. It allows for cultivation of hemp on the lands owned by the indigenous community.
OWP will supply the co-op with registered genetics in the form of seeds or plantlets to grow hemp and non-psychoactive cannabis. Under this agreement, OWP will advise the co-op on best practices in cultivation, harvesting and processing of the raw material. The agreement also provides for OWP to purchase the raw biomass produced under this agreement upon meeting quality control standards and lab testing. One World Pharma intends to then refine the biomass at its state-of-the-art facility for export. The hemp-derived ingredients are expected to be used in Consumer Packaged Goods (CPG) and Over The Counter (OTC) products being manufactured worldwide.
“One World Pharma has been extraordinary to our people and the opportunity to partner with such a visionary company will be outstanding,” stated Ariel Huetio Prieto, the founder and the legal representative of the co-op. “The technology and cultivation methods that One World Pharma brings are phenomenal. More than anything, we are working together as partners to offer a better life for our people, and for all of Colombia.”
“It is our mission to partner with the local indigenous communities and small farmers to produce high quality hemp ingredients for international sale. We expect this partnership will provide the indigenous community with the ability to participate in the global supply chain. Our process is a holistic approach that is expected to create a thriving local economy while generating significant revenue for our shareholders,” stated Craig Ellins, CEO of One World Pharma.
About One World Pharma
One World Pharma Inc. is the U.S. parent company of One World Pharma S.A.S, a fully licensed cannabis and hemp producer with offices and operations in Bogota and Popayan, Colombia. One World Pharma planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia, for research purposes and expects to begin harvesting commercially in the second quarter of 2020. The company intends to supply the highest quality cannabis and hemp derivatives in crude oil, distillate and isolate forms with industrial scale production to serve global cannabis demand. Its products will be produced and tested to GMP standards.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, risks related to operating in Colombia, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company's Current Report on 8-K filed with the Securities and Exchange Commission on July 12, 2019, which is available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.